Desidustat in the Treatment of Anemia in CKD on Dialysis Patients
NCT ID: NCT04215120
Last Updated: 2021-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
392 participants
INTERVENTIONAL
2020-01-04
2021-09-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Desidustat oral tablet
Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.
Desidustat Oral Tablet
Desidustat tablet
Epoetin Injection
Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.
Epoetin Alfa
Epoetin Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Desidustat Oral Tablet
Desidustat tablet
Epoetin Alfa
Epoetin Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3\.
1. Patients will be considered not treated with erythropoietin analogue (Epoetin and Darbepoeitin) if they have not received erythropoietin analogue for at least 4 weeks and Mircera® for at least 8 weeks prior to screening visit. OR
2. Patients who are on ESA therapy must be on stable dose for 4 weeks prior to enrollment (≤30% of dose change).
4\. Patients on hemodialysis (≥2 times in a week) for at least 12 weeks prior to screening visit and have access consisting of an arteriovenous fistula, AV graft, or catheter (permanent/temporary).
5\. Patients with no planned change in dialysis modality and with no planned renal transplant during study period.
6\. Left ventricular ejection fraction ≥40% by echocardiogram prior to randomization.
7\. No iron, folate or Vitamin B12 deficiency.
8\. Females of childbearing potential, must agree to use one of the approved contraception methods, from screening until completion of the follow-up visit.
Exclusion Criteria
2. History of previous or concurrent cancer.
3. Serologic status reflecting active hepatitis B or C infection or Human immunodeficiency virus (HIV) infection.
4. Active infection at initiation of study.
5. History of renal transplant.
6. Uncontrolled hypertension (defined as SBP \>180 mmHg or DBP \>100 mmHg) at screening visit (before dialysis).
7. Patient on high rhEPO dose at screening visit. \[High dose defined as an epoetin dose of ≥450 IU/kg/week intravenous or ≥ 300 IU/kg/week subcutaneous or darbepoetin dose of ≥1.5 µg/kg/week subcutaneous\].
8. Major surgery within 90 days of the first day of study drug dosing, and minor surgery within 30 days of the first day of study drug dosing.
9. Unable to swallow tablets or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as; malabsorption syndrome, resection of the small bowel or poorly controlled inflammatory bowel disease affecting the small intestine.
10. History of uncontrolled autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (ITP) or thalassemia.
11. Presence or a history of bleeding disorders or clinical conditions (e.g. gastrointestinal \[GI\] bleeding or constitutional disorders) that may increase risk of life-threatening bleeding.
12. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
13. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Desidustat or Epoetin alfa or to any erythropoieisis-stimulating agent.
14. Pregnant and breastfeeding women.
15. Current life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
16. Other laboratory abnormalities that, in the opinion of the investigator, would compromise the patient's safety or interfere with data interpretation.
17. Presence of other clinically significant systemic disorders or diseases (e.g., respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement) which, in the Investigator's opinion, could compromise the patient's safety.
18. History of significant alcoholism or drug abuse within the past 1 year. History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco/nicotine products (more than 10 times per day).
19. History of difficulty with donating blood.
20. History or presence of any clinically significant electrocardiogram (ECG) abnormalities during screening.
21. Participants who have participated in any drug research study other than the present trial within past 3 months.
22. Participants who have donated one unit (350 ml) of blood in the past 3 months or history of whole blood transfusion in last 120 days prior to entry in the study.
23. Existing clinically active chronic inflammatory disease (RA, Celiac disease, UC, Crohns disease)
24. In case of DM patients, HbA1c \>9%.
25. Female volunteers with following criteria will not be recruited:
* History of pregnancy or lactation in the past 3 months
* Fertile female volunteers not protected against pregnancy by adequate long- term anti-fertility measures
* History of less than 1 year of menopause and not using adequate long-term anti-fertility measures
* Positive urine pregnancy test at Visit 2
* Positive serum β-hCG level at the screening visit
26. Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification or history of myocardial infarction prior to first dose with study drug.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zydus Lifesciences Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr Deven Parmar, MD
Role: STUDY_DIRECTOR
Zydus Lifesciences Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karnavati Hospital Pvt.Ltd
Ahmedabad, Gujarat, India
Shalby Hospital,
Ahmedabad, Gujarat, India
DHS Multispecialty Hospital
Ahmedabad, Gujarat, India
Chopda Medicare & Research Centre Pvt. Ltd
Nashik, Maharashtra, India
Aditya Birla Memorial Hospital
Pune, Maharashtra, India
Eternal Hospital
Jaipur, Rajasthan, India
Star Hospital
Hyderabad, Telangana, India
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DESI.19.001.01
Identifier Type: -
Identifier Source: org_study_id